We're using cookies to give you the best experience on our site. Cookies are files stored in your browser and are used by most websites to help personalise your web experience.

By continuing to use our website without changing the settings, you're agreeing to our use of cookies.

Find out more
For more information, go to

Early and aggressive treatment in RA

Issue 33 Synovium (Summer 2011)

Download this issue (opens in new window)(303.8 KB)

Some Synovium readers may remember the days when first-line treatment, once the diagnosis of rheumatoid arthritis was established, was a non-steroidal anti-inflammatory drug (NSAID), with more powerful disease-modifying drugs (DMARDs) being saved for later – sometimes much later in the treatment pathway. Earlier interventions with DMARDs are now the norm and further evidence to support early and aggressive treatments has been published in Arthritis Care and Research.1 Analysis of a database of around 4825 patients treated with DMARDs demonstrated that greater remission rates were achieved with earlier initiation of treatment. Results were similar for both biological agents (anti-tumour necrosis factor drugs) and non-biological (e.g. methotrexate).

Synovium archives

Browse previous issues of Synovium (all issues available as downloadable PDFs)

We're now

Versus Arthritis.

You're being taken through to our new website in order to finish your donation.

Thank you for your generosity.

For more information, go to
Arthritis Research UK fund research into the cause, treatment and cure of arthritis. You can support Arthritis Research UK by volunteering, donating or visiting our shops.